

Pascale GROSCLAUDE - publications 2014-2020

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronic diseases, intervenTions, methodologY

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juin 2020

2020

1. Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, Maciejczyk A, Rodríguez-Barranco M, Zadnik V, Minicozzi P, EUROCARE-5 Working Group (**Grosclaude P** collaborator). Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. Arch Gynecol Obstet. 2020;301(2):591-602. doi:10.1007/s00404-019-05412-5.
2. Biscond M, Guimbaud R, Digue L, Cirilo-Cassaigne I, Bousser V, Oum-Sack E, Goddard J, Bauvin E, Delpierre C, **Grosclaude P**, Lamy S. How does comorbidity affect colon cancer patients' care trajectory? Results from the French EvaCCoR cohort study [published online ahead of print, 2020 Apr 16]. Clin Res Hepatol Gastroenterol. 2020;S2210-7401(20)30097-8. doi:10.1016/j.clinre.2020.03.022.
3. Bouvier AM, Robaszekiewicz M, Jooste V, Cariou M, Drouillard A, Bouvier V, Nousbaum JB, French Network of Cancer Registries (FRANCIM) (**Grosclaude P** collaborator). Trends in incidence of small bowel cancer according to histology: a population-based study. J Gastroenterol. 2020;55(2):181-188. doi:10.1007/s00535-019-01636-z
4. Druel V, Gimenez L, Paricaud K, Delord JP, **Grosclaude P**, Boussier N, Rougé Bugat ME. Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancer. BMC Cancer. 2020;20(1):495. Published 2020 Jun 1. doi:10.1186/s12885-020-06993-0.
5. Foucan AS, **Grosclaude P**, Bousser V, Bauvin E, Smith D, Andre-Fardeau C, Daubisse-Marliac L, Mathoulin-Pelissier S, Amadeo B, Coureau G. Management of colon cancer patients: A comprehensive analysis of the absence of multidisciplinary team meetings in two French departments [published online ahead of print, 2020 Apr 28]. Clin Res Hepatol Gastroenterol. 2020;S2210-7401(20)30087-5. doi:10.1016/j.clinre.2020.02.020.
6. **Grosclaude P**, Azria D, Guimbaud R, Thibault S, Daubisse L, Cartron G, Renaudie MJ, Dalbies PA, Delord JP, Bauvin E. Impact du SARS-CoV2 sur la structuration de la prise en charge du cancer : exemple de la tenue des RCP de cancérologie en Occitanie [COVID-19 impact on the cancer care structuration: example of the multidisciplinary team meeting dedicated to oncology in Occitanie] [published online ahead of print, 2020 May 18]. Bull Cancer. 2020;10.1016/j.bulcan.2020.05.001. doi:10.1016/j.bulcan.2020.05.001.
7. Villers A, Bessaoud F, Trétarre B, **Grosclaude P**, Malavaud B, Rebillard X, Iborra F, Daubisse L, Malavaud S, Roobol M, Heijnsdijk EA, de Koning HJ, J Hugosson J, Rischmann P, Soulié M. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-

up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). *Prog Urol*. 2020;30(5):252-260. doi:10.1016/j.purol.2020.02.011.

2019

1. Bielska-Lasota M, Rossi S, Krzyżak M, et al. EUROCORE-5 Working Group (**Grosclaude P** collaborator). Reasons for low cervical cancer survival in new accession European Union countries: a EUROCORE-5 study [published online ahead of print, 2019 Dec 18]. *Arch Gynecol Obstet*. 2019;10.1007/s00404-019-05412-5. doi:10.1007/s00404-019-05412-5.
2. Bouvier AM, Robaszekiewicz M, Jooste V, et al. French Network of Cancer Registries (FRANCIM) (**Grosclaude P** collaborator). Trends in incidence of small bowel cancer according to histology: a population-based study [published online ahead of print, 2019 Oct 19]. *J Gastroenterol*. 2019;10.1007/s00535-019-01636-z. doi:10.1007/s00535-019-01636-z
3. Bryere J, Tron L, Menvielle G, Launoy G; French Network of Cancer Registries (FRANCIM) (**Grosclaude P** collaborator). The respective parts of incidence and lethality in socioeconomic differences in cancer mortality. An analysis of the French network Cancer registries (FRANCIM) data. *Int J Equity Health*. 2019;18(1):189. Published 2019 Dec 3. doi:10.1186/s12939-019-1087-y.
4. Cowppli-Bony A, Colonna M, Ligier K, Jooste V, Defossez G, Monnereau A; le Réseau Francim; Réseau des registres de cancer Francim. **Grosclaude P** collaborator) [Descriptive epidemiology of cancer in metropolitan France: Incidence, survival and prevalence]. *Bull Cancer*. 2019. Jul-Aug 106 (7-8), 617-634. doi: 10.1016/j.bulcan.2018.11.016.
5. Gatta G, Trama A, Capocaccia R; RARECARENet Working Group. (**Grosclaude P** collaborator) Epidemiology of rare cancers and inequalities in oncologic outcomes. *Eur J Surg Oncol*. 2019 Jan;45(1):3-11. doi: 10.1016/j.ejso.2017.08.018.
6. Gosset A, Cohade C, **Grosclaude P**, Oumsack E, Dalenc F, Montagut M, Parinaud J, Vaysse C. [Regional state-of-the-art of the access to oncofertility consultation for young women with breast cancer]. *Gynecol Obstet Fertil Senol*. 2019 Oct;47(10):732-738. doi:10.1016/j.gofs.2019.08.005.
7. Imbimbo M, Maury JM, Garassino M, Girard N; RARECAREnet Working Group. (**Grosclaude P** collaborator) Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. *Eur J Surg Oncol*. 2019 Jan;45(1):75-80. doi: 10.1016/j.ejso.2018.01.078.
8. Lamy S, Guimbaud R, Digue L, Cirilo-Cassaigne I, Bousser V, Oum-Sack E, Goddard J, Bauvin E, Delpierre C, **Grosclaude P**; EvaCCoR Group. Are there variations in adherence to colorectal cancer clinical guidelines depending on treatment place and recommendation novelty? The French EvaCCoR observational study. *Clin Res Hepatol Gastroenterol*. 2019 Jun;43(3):346-356. doi: 10.1016/j.clinre.2018.10.008.
9. Lamy S, Laurent G, Lepage B, **Grosclaude P**, Delpierre C. Impact of comorbidity in DBLCL: direct and indirect effects on survival through unplanned chemotherapy dose reduction. *J Intern Med*. 2019 Apr;285(4):472-474. doi: 10.1111/joim.12879.
10. Lamy S, Molinié F, Daubisse-Marliac L, Cowppli-Bony A, Ayrault-Piault S, Fournier E, Woronoff AS, Delpierre C, **Grosclaude P**. Using ecological socioeconomic position (SEP) measures to deal with sample bias introduced by incomplete individual-level measures: inequalities in breast cancer stage at diagnosis as an example. *BMC Public Health*. 2019 Jul 2;19(1):857. doi:10.1186/s12889-019-7220-4.
11. Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK; RARECARENet Working Group. (**Grosclaude P** collaborator) Treatment challenges in and outside a specialist network setting:

- Pancreatic neuroendocrine tumours. *Eur J Surg Oncol.* 2019 Jan;45(1):46-51. doi: 10.1016/j.ejso.2017.08.019.
12. Nicolai N, Biondi D, Catanzaro MA, Colecchia M, Trama A; RARECAREnet Working Group. (**Grosclaude P** collaborator) Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. *Eur J Surg Oncol.* 2019 Jan;45(1):60-66. doi: 10.1016/j.ejso.2018.02.006.
 13. Orlandi E, Alfieri S, Simon C, Trama A, Licitra L; RARECAREnet Working Group. (**Grosclaude P** collaborator) Treatment challenges in and outside a network setting: Head and neck cancers. *Eur J Surg Oncol.* 2019 Jan;45(1):40-45. doi: 10.1016/j.ejso.2018.02.007.
 14. Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, Gronchi A; RARECAREnet Working Group. (**Grosclaude P** collaborator) Treatment challenges in and outside a network setting: Soft tissue sarcomas. *Eur J Surg Oncol.* 2019 Jan;45(1):31-39. doi: 10.1016/j.ejso.2017.09.015.
 15. Piel C, Pouchieu C, Carles C, Béziat B, Boulanger M, Bureau M, Busson A, Grüber A, Lecluse Y, Migault L, Renier M, Rondeau V, Schwall X, Tual S; AGRICAN group (**Grosclaude P** collaborator), Pierre L, Baldi I. Agricultural exposures to carbamate herbicides and fungicides and central nervous system tumour incidence in the cohort AGRICAN. *Environ Int.* 2019 Sep;130:104876. doi:10.1016/j.envint.2019.05.070.
 16. Pons-Tostivint E, Daubisse-Marliac L, **Grosclaude P**, Oum Sack E, Goddard J, Morel C, Dunet C, Sibrac L, Lagadic C, Bauvin E, Bergé Y, Bernard-Marty C, Vaysse C, Lacaze JLL; EvaSein Group. Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study. *Breast.* 2019 Aug;46:170-177. doi: 10.1016/j.breast.2019.06.001.
 17. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECAREnet Working Group. (**Grosclaude P** collaborator). Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol.* 2019 Jan;45(1):67-74. doi: 10.1016/j.ejso.2017.09.025.
 18. Tual S, Busson A, Boulanger M, Renier M, Piel C, Pouchieu C, Pons R, Perrier S, Levêque-Morlais N, Karuranga P, Lemarchand C; AGRICAN-Group (**Grosclaude P** collaborator), Marcotullio E, Guizard AV, Monnereau A, Baldi I, Lebailly P. Occupational exposure to pesticides and multiple myeloma in the AGRICAN cohort. *Cancer Causes Control.* 2019 Nov;30(11):1243-1250. doi:10.1007/s10552-019-01230-x.

2018

1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group (**Grosclaude P** collab.) Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet.* 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3.
2. Bryere J, Dejardin O, Launay L, Colonna M, **Grosclaude P**, Launoy G; French Network of Cancer Registries (FRANCIM). Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study. *Eur J Cancer Prev.* 2018 Jul;27(4):391-398. doi: 10.1097/CEJ.0000000000000326.

3. Conte C, Palmaro A, **Grosclaude P**, Daubisse-Marliac L, Despas F, Lapeyre-Mestre M. A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. *Medicine (Baltimore)*. 2018 Jan;97(2):e9418. doi: 10.1097/MD.00000000000009418.
4. Fondain M, Dereure O, Uhry Z, Guizard AV, Woronoff AS, Colonna M, Molinie F, Bara S, Velten M, Marrer E, **Grosclaude P**, Lapôte-Ledoux B, Tretarre B, Guillot B. Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey. *J Eur Acad Dermatol Venereol*. 2018 Aug;32(8):1292-1296. doi: 10.1111/jdv.14798.

2017

1. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group (**Grosclaude P** collaborator). Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol*. 2017 May;4(5):e202-e217. doi: 10.1016/S2352-3026(17)30052-2.
2. Bryere J, Pornet C, Copin N, Launay L, Gusto G, **Grosclaude P**, Delpierre C, Lang T, Lantieri O, Dejardin O, Launoy G. Assessment of the ecological bias of seven aggregate social deprivation indices. *BMC Public Health*. 2017 Jan 17;17(1):86. doi: 10.1186/s12889-016-4007-8.
3. Cowppli-Bony A, Uhry Z, Remontet L, Voirin N, Guizard AV, Trétarre B, Bouvier AM, Colonna M, Bossard N, Woronoff AS, **Grosclaude P**; French Network of Cancer Registries (FRANCIM). Survival of solid cancer patients in France, 1989-2013: a population-based study. *Eur J Cancer Prev*. 2017 Jun 8. doi: 10.1097/CEJ.0000000000000372.
4. Cowppli-Bony A, Uhry Z, Remontet L, Voirin N, Guizard AV, Trétarre B, Bouvier AM, Colonna M, Bossard N, Woronoff AS, **Grosclaude P**; French Network of Cancer Registries (FRANCIM). Survival of solid cancer patients in France, 1989-2013: a population-based study. *Eur J Cancer Prev*. 2017 Nov;26(6):461-468. doi: 10.1097/CEJ.0000000000000372.
5. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius D, Ardanaz E, Rubió-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R; EUROCARE-5 Working Group (**Grosclaude P** collaborator). Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. *Eur J Cancer*. 2017 May;77:140-152. doi: 10.1016/j.ejca.2017.02.023.
6. Daubisse-Marliac L, Colonna M, Trétarre B, Defossez G, Molinié F, Jéhannin-Ligier K, Marrer E; FRANCIM network, **Grosclaude P**. Long-term trends in incidence and survival of penile cancer in France. *Cancer Epidemiol*. 2017 Oct;50(Pt A):125-131. doi: 10.1016/j.canep.2017.08.014.
7. Daubisse-Marliac L, Lamy S, Lunardi P, Tollon C, Thoulouzan M, Latorzeff I, Bauvin E, **Grosclaude P**; Evacap-Oncomip. [Prostate cancer: Quality assessment of clinical management in the Midi-Pyrenean region in 2011]. *Prog Urol*. 2017 Feb;27(2):68-79. doi: 10.1016/j.purol.2016.12.007.
8. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, Siesling S, van der Zwan JM, Van Eycken L, Visser O, Žakelj MP, Anderson LA, Bella F, Kaire I, Otter R, Stiller CA, Trama A; RARECAREnet working group. (**Grosclaude P** collaborator) Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. *Lancet Oncol*. 2017 Aug;18(8):1022-1039. doi: 10.1016/S1470-2045(17)30445-X.

9. **Grosclaude P**, Roche L, Fuentes-Raspall R, Larrañaga N; GRELL EUROCARE-5 Working Group. Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. *Eur J Cancer Prev.* 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S114-S120. doi: 10.1097/CEJ.0000000000000304.
10. Jéhannin-Ligier K, Dejardin O, Lapôtre-Ledoux B, Bara S, Coureau G, **Grosclaude P**, Marrer E, Molinié F, Trétarre B, Velten M, Woronoff AS, Colonna M, Guizard AV. Oral cancer characteristics in France: Descriptive epidemiology for early detection. *J Stomatol Oral Maxillofac Surg.* 2017 Apr;118(2):84-89. doi: 10.1016/j.jormas.2017.02.003.
11. Lamy S, Ducros D, Diméglio C, Colineaux H, Fantin R, Berger E, **Grosclaude P**, Delpierre C, Bouhanick B. Disentangling the influence of living place and socioeconomic position on health services use among diabetes patients: A population-based study. *PLoS One.* 2017 Nov 29;12(11):e0188295. doi: 10.1371/journal.pone.0188295.
12. Lunardi P, Ploussard G, **Grosclaude P**, Roumiguié M, Soulié M, Beauval JB, Malavaud B. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. *World J Urol.* 2017 Apr;35(4):587-593. doi: 10.1007/s00345-016-1900-9.
13. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; CONCORD Working Group. (Grosclaude P collaborator) Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [*Gynecol. Oncol.* 144 (2017) 396-404]. *Gynecol Oncol.* 2017 Dec;147(3):725. doi: 10.1016/j.ygyno.2017.06.033.
14. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C; CONCORD Working Group; Africa. (Grosclaude P collaborator) Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [*Gynecol. Oncol.* 144 (2017) 405-413]. *Gynecol Oncol.* 2017 Dec;147(3):726. doi: 10.1016/j.ygyno.2017.06.032.
15. Palmaro A, Gauthier M, Conte C, **Grosclaude P**, Despas F, Lapeyre-Mestre M. Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry. *Medicine (Baltimore).* 2017 Mar;96(12):e6189. doi: 10.1097/MD.00000000000006189.
16. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesselting P, Shin HY, Stiller CA; IICC-3 contributors (Grosclaude P collaborator). International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol.* 2017 Jun;18(6):719-731. doi: 10.1016/S1470-2045(17)30186-9.

2016

1. Ayrault-Piault S, **Grosclaude P**, Daubisse-Marliac L, Pascal J, Leux C, Fournier E, Tagri AD, Métais M, Lombraill P, Woronoff AS, Molinié F. Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France). *Int J Cancer.* 2016 Nov 1;139(9):1983-93. doi: 10.1002/ijc.30266.
2. Kerleau C, Guizard AV, Daubisse-Marliac L, Heutte N, Mercier M, **Grosclaude P**, Joly F; French Network of Cancer Registries (FRANCIM). Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. *Eur J Cancer.* 2016 Aug;63:143-53. doi: 10.1016/j.ejca.2016.05.020.
3. Lang T, Bidault E, Villeval M, Alias F, Gandouet B, Servat M, Theis I, Breton E, Haschar-Noé N, **Grosclaude P**. A health equity impact assessment umbrella program (AAPRISS) to tackle social

inequalities in health: program description. *Glob Health Promot.* 2016 Sep;23(3):54-62. doi: 10.1177/1757975914568127.

4. Lamy S, Bettioli C, **Grosclaude P**, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study. *BMC Health Serv Res.* 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9.
5. Muller J, **Grosclaude P**, Lapôtre-Ledoux B, Woronoff AS, Guizard AV, Bara S, Colonna M, Troussard X, Bouvier V, Trétarre B, Velten M, Jégu J. Trends in the risk of second primary cancer among bladder cancer survivors: a population-based cohort of 10 047 patients. *BJU Int.* 2016 Jul;118(1):53-9. doi: 10.1111/bju.13351.
6. Neumann F, Jégu J, Mouglin C, Prétet JL, Guizard AV, Lapôtre-Ledoux B, Bara S, Bouvier V, Colonna M, Troussard X, Trétarre B, **Grosclaude P**, Velten M, Woronoff AS. Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. *Prev Med.* 2016 Jun 28;90:52-58. doi: 10.1016/j.ypmed.2016.06.041.
7. Rougé Bugat ME, Omnes C, Delpierre C, Escourrou E, Boussier N, Oustric S, Delord JP, Bauvin E, **Grosclaude P**. Primary care physicians and oncologists are partners in cancer announcement. *Support Care Cancer.* 2016 Jun;24(6):2473-9. doi: 10.1007/s00520-015-3049-2.
8. Villeval M, Bidault E, Lang T; pour le groupe AAPRISS (**Grosclaude P**). Evaluation d'impact sur la santé et évaluation d'impact sur l'équité en santé : éventail de pratiques et questions de recherche. *Glob Health Promot.* 2016 Sep;23(3):86-94. doi: 10.1177/1757975915570139.
9. Villeval M, Bidault E, Shoveller J, Alias F, Basson JC, Frasse C, Génolini JP, Pons E, Verbiguié D, **Grosclaude P**, Lang T. Enabling the transferability of complex interventions: exploring the combination of an intervention's key functions and implementation. *Int J Public Health.* 2016 Dec;61(9):1031-1038.

2015

1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group (**Grosclaude P**). Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet.* 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Erratum in: *Lancet.* 2015 Mar 14;385(9972):946.
2. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, **Grosclaude P**, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)[†]. *Ann Oncol.* 2015 May;26(5):865-72. doi: 10.1093/annonc/mdu360.

3. Colonna M, Mitton N, Bossard N, Belot A, **Grosclaude P**; French Network of Cancer Registries (FRANCIM). Total and partial cancer prevalence in the adult French population in 2008. *BMC Cancer*. 2015 Mar 19;15:153. doi: 10.1186/s12885-015-1168-2.
4. Colonna M, Uhry Z, Guizard AV, Delafosse P, Schwartz C, Belot A, **Grosclaude P**; FRANCIM network. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. *Cancer Epidemiol*. 2015 Aug;39(4):511-8. doi: 10.1016/j.canep.2015.04.015.
5. Ducros D, Nicoules V, Chehoud H, Bayle A, Souche A, Tanguy M, Valière JP, Cayla F, **Grosclaude P**. [Use of medical and administrative databases to measure social health inequalities]. *Sante Publique*. 2015 May-Jun;27(3):383-94. French. Erratum in: *Sante Publique*. 2015 Jul-Aug;27(4):609.
6. **Grosclaude P**, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M; réseau Francim. [Prostate cancer incidence and mortality trends in France from 1980 to 2011]. *Prog Urol*. 2015 Jul;25(9):536-42. doi: 10.1016/j.purol.2015.04.011.
7. Lunardi P, Beauval J, Gamé X, Roumiguié M, Thoulouzan M, Doumerc N, Huyghe E, Soulié M, Rischmann P, **Grosclaude P**, Malavaud B. Sur-traitement et sous traitement du cancer de la prostate en Midi-Pyrénées. *Prog Urol*. 2015 Nov;25(13):756. doi: 10.1016/j.purol.2015.08.083.
8. Lunardi P, Beauval J, Gamé X, Roumiguié M, Thoulouzan M, Doumerc N, Huyghe E, Soulié M, Rischmann P, **Grosclaude P**, Malavaud B. Âge, comorbidités et cancer de la prostate : où en est-on du sur-diagnostic en Midi-Pyrénées ? *Prog Urol*. 2015 Nov;25(13):755-6. doi: 10.1016/j.purol.2015.08.082.
9. Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, Capocaccia R, Iwaz J, Monnereau A, Troussard X, Sant M, Maynadié M, Giorgi R; EURO CARE-5 Working Group; CENSUR Working Survival Group. (**Grosclaude P**) Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EURO CARE-5). *Lancet Haematol*. 2015 Nov;2(11):e481-91. doi: 10.1016/S2352-3026(15)00155-6.
10. Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, **Grosclaude P**. Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. *Support Care Cancer*. 2015 Dec;23(12):3473-80. doi: 10.1007/s00520-015-2705-x.
11. Tournaire M, Devouche E, Espié M, Asselain B, Levadou A, Cabau A, Dunbavand A, **Grosclaude P**, Epelboin S. Cancer Risk in Women Exposed to Diethylstilbestrol in Utero. *Therapie*. 2015 Sep-Oct;70(5):433-41. doi: 10.2515/therapie/2015030.
12. Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, **Grosclaude P**, Guizard AV, Delafosse P, Bara S, Velten M, Lapôtre-Ledoux B, Ligier K, Léone N, Arveux P, Uhry Z. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. *Gynecol Oncol*. 2015 Nov;139(2):324-9. doi: 10.1016/j.ygyno.2015.09.013.
13. Villeval M, Bidault E, Gaborit E, **Grosclaude P**, Haschar-Noé N, Lang T; groupe AAPRISS. [An intervention research program (AAPRISS) to reduce social inequalities in health: methods and validation]. *Can J Public Health*. 2015 Oct 3;106(6):e434-41. doi: 10.17269/cjph.106.4955.

2014

1. Binder-Foucard F, Bossard N, Delafosse P, Belot A, Woronoff AS, Remontet L; French network of cancer registries (Francim) (**Grosclaude P**). Cancer incidence and mortality in France over the 1980-2012

- period: solid tumors. Rev Epidemiol Sante Publique. 2014 Apr;62(2):95-108. doi: 10.1016/j.respe.2013.11.073.
2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; EUROCARE-5 Working Group (**Grosclaude P**). Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan;15(1):23-34. doi: 10.1016/S1470-2045(13)70546-1.
 3. Mathoulin-Pélissier S, Chevreau C, Bellera C, Bauvin E, Savès M, **Grosclaude P**, Albert S, Goddard J, Le Guellec S, Delannes M, Bui BN, Mendiboure J, Stoeckle E, Coindre JM, Kantor G, Kind M, Cowppli-Bony A, Hoppe S, Italiano A. Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study. Ann Oncol. 2014 Jan;25(1):225-31. doi: 10.1093/annonc/mdt407.
 4. Minicozzi P, Bouvier AM, Faivre J, Sant M; Study working group (**Grosclaude P**). Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients. Dig Liver Dis. 2014 Jul;46(7):645-51. doi: 10.1016/j.dld.2014.03.009.
 5. Stiller CA, Trama A, Brewster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; RARECARE Working Group (**Grosclaude P**). Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiol. 2014 Dec;38(6):670-8. doi: 10.1016/j.canep.2014.09.009.
 6. Villeval M, Ginsbourger T, Bidault E, Alias F, Delpierre C, Gaborit E, Kelly-Irving M, Manuello P, **Grosclaude P**, Lang T; AAPRISS. [Interdisciplinarity in action: "trap-words" in interdisciplinary research]. Sante Publique. 2014 Mar-Apr;26(2):155-63.